Sodium–glucose cotransport 2 (SGLT2) inhibitors are drugs approved for type 2 diabetes mellitus treatment that also exert cardiorenal protection in patients with and without diabetes, independent of lowering the plasma glucose concentration [34]. Here, SLC5A2 is linked to type 2 diabetes mellitus.